FDA Approves Blood Test for Alzheimer's Disease: A Major Step Toward Lowering the Barrier to Early Screening

FDA Approves First Blood Test to Aid in Alzheimer's Disease Diagnosis

The U.S. Food and Drug Administration (FDA) recently approved a blood test designed to aid in the evaluation of Alzheimer's disease. This decision marks a significant milestone in the diagnosis of neurodegenerative diseases and has the potential to dramatically lower the barrier for patients seeking early diagnosis.

For years, confirming an Alzheimer's diagnosis has relied primarily on two methods: expensive positron emission tomography (PET) brain imaging and invasive cerebrospinal fluid (CSF) testing via lumbar puncture. PET brain imaging works by injecting radioactive tracers (such as Florbetapir or Florbetaben) into the patient, tracking how these tracers bind to amyloid plaques in the brain, and generating high-resolution images of brain pathology. A single PET scan in the United States typically costs between $3,000 and $7,000, requires specialized equipment and radiochemistry lab support, and is available at only a few hundred facilities nationwide. CSF testing requires obtaining samples through lumbar puncture to measure concentrations of key proteins. While the technique is well-established, it is invasive, and some patients experience post-procedure headaches and other side effects, leading to low acceptance. Both methods are considered the gold standard for diagnostic accuracy, but their high cost, limited accessibility, and poor patient experience have been major obstacles to early screening and intervention. The approval of a blood test is precisely aimed at addressing these long-standing clinical pain points.

Why the Alzheimer's Blood Test Is So Significant

One of the core pathological hallmarks of Alzheimer's disease is the abnormal accumulation of beta-amyloid (amyloid beta) plaques in the brain. Traditionally, detecting these pathological markers has required expensive imaging studies or invasive lumbar puncture.

The key breakthrough of the blood test lies in its ability to measure specific biomarkers in blood plasma — such as p-tau protein and amyloid protein ratios — to indirectly reflect pathological changes in the brain. Specifically, the most closely watched plasma biomarkers include phosphorylated tau217 (p-tau217), phosphorylated tau181 (p-tau181), and the concentration ratio of Aβ42 to Aβ40. The reliable detection of these markers in blood has been made possible by technological breakthroughs in high-sensitivity detection platforms such as mass spectrometry and single molecule array (Simoa) technology, which have pushed detection limits from the nanogram level down to the femtogram level. Studies have shown that p-tau217 demonstrates extremely high accuracy in distinguishing amyloid-positive from amyloid-negative individuals, with an area under the receiver operating characteristic curve (AUC) exceeding 0.95 in multiple large-scale clinical validations — approaching the diagnostic performance of PET scans. This delivers two critical advantages:

Lower Testing Costs and Greater Healthcare Accessibility

The cost of a single blood draw test is far lower than a PET scan, and virtually all primary care facilities have the capacity to draw blood. This will enable early Alzheimer's screening to move beyond large medical centers into community clinics, benefiting a much broader population — especially elderly individuals in areas with limited healthcare resources.

Opening an Earlier Window for Therapeutic Intervention

Alzheimer's disease pathology often begins accumulating in the brain 10 to 20 years before obvious cognitive impairment symptoms appear. Neuroscience research has revealed that the disease follows a long pathological cascade: it begins with abnormal aggregation of amyloid protein in the cerebral cortex, followed by hyperphosphorylation of tau protein and formation of neurofibrillary tangles, accompanied by synaptic damage and inflammatory responses. Eventually, massive neuronal death leads to atrophy of the hippocampus and cerebral cortex, and only then do patients exhibit noticeable memory loss and cognitive decline. This pathological staging model, known as the "ATN framework" (Amyloid-Tau-Neurodegeneration), provides the theoretical basis for the clinical value of early blood testing — identifying high-risk individuals by capturing the earliest abnormal protein signals before irreversible neurological damage occurs. Low-barrier blood testing can help identify these high-risk populations, providing a more generous time window for early intervention, lifestyle modifications, and even new drug treatments.

The Synergy Between Blood Testing and Novel Antibody Therapies

You may not have noticed, but in recent years, anti-amyloid monoclonal antibody drugs targeting Alzheimer's disease (such as lecanemab and donanemab) have been successively approved. Lecanemab (brand name Leqembi, co-developed by Eisai and Biogen) and Donanemab (developed by Eli Lilly) represent a new "disease-modifying" paradigm in Alzheimer's treatment. Unlike traditional cholinesterase inhibitors that merely alleviate symptoms, these monoclonal antibodies target and clear amyloid plaques in the brain, attempting to slow disease progression at its source. In Phase III clinical trials, lecanemab slowed the rate of cognitive decline in early Alzheimer's patients by approximately 27% over 18 months.

However, these drugs also carry the risk of amyloid-related imaging abnormalities (ARIA), manifesting as brain edema or microbleeds, with approximately 12%-35% of patients experiencing varying degrees of ARIA. For this reason, the efficacy of these drugs is highly dependent on early, precise patient selection — not only confirming the presence of amyloid pathology but also performing APOE genotyping to assess ARIA risk.

The widespread availability of blood testing complements this treatment trend perfectly:

• Helps physicians quickly identify which patients might benefit from novel therapies
• Avoids unnecessary expensive PET examinations and blind medication use
• Improves the overall efficiency of the care pathway from screening to treatment

Limitations That Warrant a Rational Perspective

Despite the excitement surrounding this development, a cautious perspective is warranted. The FDA approved this test for "aid evaluation" purposes, not as a standalone diagnostic tool. This means blood test results must be interpreted in conjunction with clinical symptoms, cognitive function assessments, and other examinations — a final diagnosis cannot be made based on a single blood test alone.

Additionally, the following challenges must be addressed during clinical rollout:

• Risk of overdiagnosis: Testing positive for amyloid pathology biomarkers does not necessarily mean a person will develop Alzheimer's dementia. Epidemiological data shows that approximately 30%-40% of cognitively normal elderly individuals show amyloid positivity on PET scans, but only a portion of them will ultimately progress to clinical dementia within their lifetime. This incomplete correspondence between biomarker positivity and clinical outcomes represents the core challenge of overdiagnosis risk. In oncology, the overscreening of prostate cancer through PSA testing has already provided a sobering lesson — the detection of large numbers of indolent tumors led to unnecessary treatment and psychological burden. Alzheimer's blood testing faces similar ethical and practical dilemmas, which is an important reason the FDA positioned it as an "aid to evaluation" rather than a standalone diagnostic tool.
• Psychological burden on patients: Positive results may cause severe anxiety, and the healthcare system needs to establish accompanying genetic counseling and psychological support mechanisms
• Building follow-up systems: Patients need help correctly understanding the meaning of test results and subsequent response strategies

Outlook: The Beginning of Democratizing Alzheimer's Diagnosis

From a broader perspective, this FDA approval can be seen as an important step toward the "democratization" of Alzheimer's diagnosis. As testing technology matures and costs continue to decline, early Alzheimer's screening could become as routine as cholesterol and blood sugar checks as part of standard health examinations for middle-aged and older adults.

The urgency of this prospect cannot be overlooked. According to World Health Organization data, approximately 55 million people worldwide currently have dementia, with Alzheimer's disease accounting for 60%-70% of cases. The total number of patients is projected to exceed 150 million by 2050. In the United States alone, direct medical and long-term care costs for Alzheimer's disease and related dementias are estimated to exceed $360 billion in 2024. Even harder to quantify is the disease's impact on family caregivers — approximately 118 million informal caregivers worldwide provide unpaid care for dementia patients, and many of these caregivers themselves face serious physical and mental health challenges.

For a disease with a continuously growing global patient population that places a heavy burden on families and society, any technological advance that can lower the diagnostic threshold and expand the possibilities for early intervention deserves close attention. The approval of blood testing provides a more convenient and accessible new weapon in this race against time.

Key Takeaways